EyePoint Pharmaceuticals, Inc. announced on January 28, 2021 that the first patient has been dosed in their Phase 1 clinical trial of EYP-1901.
EYP-1901 is a potential twice-yearly sustained delivery intravitreal anti-VEGF treatment for wet age-related macular degeneration (wAMD). It is the newest of several sustained delivery drugs under study, this one promising to extend to six months the time between injections. It is initially being developed as a treatment for wAMD, but researchers are looking forward to the added potential for treatment of diabetic retinopathy and retinal vein occlusion.
The company is looking forward to seeing initial data from the Phase 1 trial as early as the second half of 2021.
Source: EyePoint Pharmaceuticals, Inc.